BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
BRAIN Biotech AG, a leading provider of specialised enzymes and innovative biological solutions for industry, has published its financial results for the first nine months of the 2024/25 fiscal year.
- BRAINBiocatalysts with +8.1% year-on-year revenue growth
- Perillic Active project from the BRAINBioIncubator segment now successfully partnered
- Cash position remains solid at €10.5 million
In the third financial quarter of 2024/25, the Group's revenue increased by 2.1% year-on-year from €13.2 million to €13.5 million. Revenue in the core business segment, BRAINBiocatalysts, rose by 8.1% to €12.8 million in the same period. In the first nine months of the 2024/2025 fiscal year, the BRAIN Biotech Group generated revenue of €38.7 million (previous year: €40.4 million). The decline in sales over the nine-month period is mainly attributable to a generally subdued economic environment and resulting delays in concluding new contracts for the contract research business within the BRAINBioIncubator segment.
Consolidated adjusted EBITDA improved nicely in the nine-month period from €-1.2 million to €-0.4 million. This was mainly due to reduced personnel costs resulting from a smaller number of employees and strict expenditures management. The cash position of the company remains solid, amounting to €10.5 million in cash and cash equivalents.
“Despite the generally muted economic environment and the ongoing US dollar weakness we recorded encouraging growth momentum in our core enzyme segment during the third quarter. The Group's successful focus on the enzyme business, combined with consistent cost management, is now also reflected in a positive EBITDA for the quarter.
